Veracyte Inc. (VCYT) Options Positioning, Max Pain & Unusual Sweeps

$50.01 -4.14% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $49.76

Veracyte Inc. (VCYT) earns a Roarable Rating of B (Buy) with 73/100 RQD Confidence. High-quality cash engine (70% profit margin, 5% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B β€’ BUY Cap $4.02B
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on VCYT Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is VCYT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Veracyte Inc. (NASDAQ: VCYT) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 73/100 at a spot price of $50.01 (-4.14% 1D, market cap $4.02B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 16/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 11/20. Across 1016 tracked Health Care issuers, VCYT ranks #50 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does VCYT compare to CDNA and CELC in the Health Care sector?
β–Ό

Within the Health Care sector (Medical Specialities), VCYT carries a Roarable B (73/100 RQD), trailing P/E of 63.2x, gross margin of 70.1%, and ROIC of 4.6%. By comparison, CDNA (CareDx Inc.) holds a B- grade (71/100 RQD, P/E N/A, ROIC -8.2%, cap $4.59B) and CELC (Celcuity Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $3.38B). Among the 5-stock peer group, CON leads on earnings multiple (31.6x) while CON leads on capital efficiency (19.7% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for VCYT?
β–Ό

Per VCYT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001384101), Veracyte Inc. generated $517.1M in revenue (+16.0% YoY), $66.4M in net income, and $126.6M in free cash flow against $1.41B in total assets and $43.4M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Priced at 63x earningsβ€”high expectations leave less room for a lukewarm quarter.. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $49.75 (-0.51%)🧬 Cannibal Buyback (-0.96% YoY Shares)βš™οΈ Cash Engine: 14/20 (B-) β€’ 24.5% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record: Scores of 73/100 (B) historically ranked in the Top 13% of excess returns over the next 90 days (+7.1% avg 90D alpha vs SPY β€’ 69.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERBUY β€’ B
025507510073
3-of-3 JEV AI Jury Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C+ Β· Rk B+
Cash (14)Whales (16)SEC (18)Macro (14)CEO (11)
Each axis scored 0–20
12M PRICE TARGET CONE+6.8% Base Target
$64 Bull$53 Base$41 Bear
πŸ“¬ FREE VCYT RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for VCYT)Realized 20D OHLCV Swing Band: Β±10.6%
Deterministic 5-Pillar Attribution (73/100 Composite)
πŸ” WHY VCYT SCORES 73/100 (B) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (25% of score)

Altman Z-Score 26.00 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 9/9

β–² #2 Bullish Driver: Whale & Options Positioning+16/20 pts (22% of score)

20D Institutional Volume Accumulation (Β±10.6% realized swing band)

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution11/20 pts (-9 pt drag)

Cannibal Buyback (-0.96% YoY Shares) & executive Form 4 sales trim 9 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
65
Grade C+$43.51+6.2% Next Q
Q2 (-2Q)
68
Grade B-$46.22+8.8% Next Q
Q3 (-1Q)
70
Grade B$50.31-0.6% Next Q
Current
73
Grade B$50.01+7.1% Hist 90D Ξ±
Trajectory: C+ (65) β†’ B (73)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

βš”οΈ Adversarial Opposing Case: Why the VCYT Bull Thesis Could Fail

Gideon Ashmere Forensic Desk β†’

Even with a 73/100 (B) score, VCYT faces multiple-compression risk if 63.2x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Priced at 63x earningsβ€”high expectations leave less room for a lukewarm quarter.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-0.96% YoY Shares) β€” any gross margin slip below 67.6% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($44.95) or 200D SMA ($42.97) invalidates the momentum regime and cuts Target Base ($53.39) toward Bear Floor ($41.01).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $VCYTβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œVCYT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
CALL VS. PUT WHALE SHARE
β€” (No Active Options Snapshot)
Put/Call Ratio: β€” (No Active Options Snapshot)
MAX-PAIN EXPIRATION MAGNET
β€” (No Active Options Snapshot)
No active options chain max-pain snapshot on file
HISTORICAL 20D VOLATILITY SWING
Β±10.6%
Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (VCYT)

β€” (No Active Options Snapshot) β€” No unusual CBOE strike concentration anomalies recorded in the current database snapshot for VCYT.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

πŸ† Enter Free $100K Paper Arena β†’
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating VCYT & AI Leaders Without Chasing Tops

  • βœ“Institutional whale strikes & implied earnings move audit on VCYT
  • βœ“How disciplined traders manage risk using pre-published trigger & invalidation levels
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
VCYT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +49.51%⚑ TESTING RESISTANCE
2026-11-03O $52.17H $52.17L $50.01C $50.01VOL 1.02M
RES: $51.93SUP: $33.13SMA50: $44.95SMA200: $42.97
$62.92$54.60$46.27$37.95$29.63RES $51.93SUP $33.13$50.012026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

VCYT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
42.9%/yr Implied 5Y Growth

vs. +16.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on VCYT today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for VCYT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for VCYT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (VCYT)

1. Head-to-Head Health Care Peer Comparison (VCYT vs. CDNA, CELC, CON, BLLN)

Industry: Medical Specialities (41 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Veracyte Inc. (VCYT) ranks #50 by composite RQD confidence (73/100, grade B) and #182 by equity capitalization ($4.02B). Within this direct 5-issuer industry benchmark cohort, CON leads on earnings valuation at 31.6x trailing P/E, while CON leads on capital efficiency and profitability with 19.7% ROIC and β€” gross margin. VCYT currently leads its immediate peer cohort in composite quantitative strength at 73/100 (B).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
VCYT ACTIVE
Veracyte Inc.
B 73/100 63.2x 70.1% 4.6% -4.14% $4.02B Benchmark Subject
CDNA
CareDx Inc.
B- 71/100 β€” β€” -8.2% +22.22% $4.59B /cdna-vs-vcyt β†’
CELC
Celcuity Inc.
E 31/100 β€” β€” -35.0% -0.24% $3.38B /celc-vs-vcyt β†’
CON
Concentra Group Holdings Parent Inc.
C+ 68/100 31.6x β€” 19.7% -2.11% $5.15B /con-vs-vcyt β†’
BLLN
BillionToOne Inc.
B- 70/100 β€” 68.3% 2.9% -1.32% $5.35B /blln-vs-vcyt β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001384101

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Veracyte Inc. (VCYT) reported GAAP revenue of $517.1M (+16.0% vs. FY2024 revenue of $445.8M , and +43.2% cumulative change since FY2023) , GAAP net income of $66.4M, operating cash flow of $136.3M, and free cash flow of $126.6M (+98.5% YoY). On the balance sheet, VCYT closed FY2025 with $1.41B in total assets against $43.4M in total debt (Altman Z-Score: 26.00, Piotroski F-Score: 9/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $517.1M $66.4M $136.3M $126.6M $1.41B $43.4M
FY2024 (FY) 2024-12-31 $445.8M $24.1M $75.1M $63.8M $1.30B $55.8M
FY2023 (FY) 2023-12-31 $361.1M -$74.4M $44.2M $28.0M $2.31B $539.8M

3. VCYT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is VCYT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Veracyte Inc. (NASDAQ: VCYT) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 73/100 at a spot price of $50.01 (-4.14% 1D, market cap $4.02B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 16/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 11/20. Across 1016 tracked Health Care issuers, VCYT ranks #50 in composite RQD confidence.

How does VCYT compare to CDNA and CELC in the Health Care sector?

Within the Health Care sector (Medical Specialities), VCYT carries a Roarable B (73/100 RQD), trailing P/E of 63.2x, gross margin of 70.1%, and ROIC of 4.6%. By comparison, CDNA (CareDx Inc.) holds a B- grade (71/100 RQD, P/E N/A, ROIC -8.2%, cap $4.59B) and CELC (Celcuity Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $3.38B). Among the 5-stock peer group, CON leads on earnings multiple (31.6x) while CON leads on capital efficiency (19.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for VCYT?

Per VCYT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001384101), Veracyte Inc. generated $517.1M in revenue (+16.0% YoY), $66.4M in net income, and $126.6M in free cash flow against $1.41B in total assets and $43.4M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Priced at 63x earningsβ€”high expectations leave less room for a lukewarm quarter.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is VCYT trading relative to its 50-day, 200-day, and 52-week technical levels?

VCYT last traded at $50.01 (-4.14% on volume of 1,015,542 shares), positioning the stock +11.26% above its 50-day simple moving average ($44.95) and +16.38% above its 200-day simple moving average ($42.97). Across its 52-week range of $29.45 to $60.91, VCYT sits at the 65.4% percentile with a 14-day RSI of 57.7 (BULLISH MOMENTUM) and an implied next-earnings move of Β±10.6% ($44.71 to $55.31).

VCYT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS β€’ SEC EDGAR Γ— CBOE Γ— FRED

What is VCYT's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for VCYT.

ROARABLE RATING BRIEF β€’ RQD 73/100 (B) βœ“ STAGE-C NUMBER FIREWALL VERIFIED

VCYT β€” Veracyte Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:22:07Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, VCYT scores 74 out of 100, a letter grade of B, with the verdict label "Roarable Buy β€” Good Risk/Reward." The score is built from five pillars:

  • Fundamental Cash Engine (14 / 20): Per the RQD rating, ROIC is 4.6% and FCF yield is 3.02%. This pillar is middling. Returns on invested capital are modest relative to the stock's valuation multiples, so the cash-generation case is supportive but not the strongest part of the thesis.
  • Whale 13F Flow (17 / 20): Per the RQD rating, this pillar reflects institutional accumulation and options positioning. It is the highest-scoring pillar, suggesting institutional interest is a meaningful component of the current rating. The holders section, however, contains no 13F detail, so the underlying flow cannot be independently examined here.
  • Insider Conviction (11 / 20): Per the RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. It is the lowest-scoring pillar, indicating weaker insider-conviction signals than the other components.
  • Macro Regime Fit (14 / 20): Per the RQD rating, beta is 1.08 and the pillar reflects sector sensitivity. A beta slightly above 1 implies the stock has moved modestly more than the broad market, so it may amplify market direction in either direction.
  • Forensic Balance Sheet (18 / 20): Per the RQD rating, Altman Z is 26, Piotroski F is 9/9, and Debt/Equity is 0.03. This is the strongest pillar and points to a low-leverage, financially robust profile.

Taken together, the rating suggests a balance-sheet-strong, institutionally supported name whose valuation (see Snapshot) is demanding relative to current returns and whose insider signals are the weakest link. Upside drivers in the source data are the forensic strength and institutional flow; the principal valuation tradeoff is the elevated P/E against a 4.6% ROIC. This is an analytical framing, not personalized advice.

Snapshot

PriceMarket CapP/E (TTM)Forward P/EEV/EBITDAEPS (TTM)Dividend YieldBeta52-Wk RangeROIC %
52.17$4.19B63.253.158.70.830%1.08$29.45 - $60.914.6%

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$517.1M$57.8M$66.4MN/A$126.6M$362.6M$43.4M
FY 2024$445.8M$16.1M$24.1MN/A$63.8M$239.1M$55.8M
FY 2023$361.1M$-85.8M$-74.4MN/A$28.0MN/A$539.8M

Per the SEC financials, revenue rose from $361.1M in FY 2023 to $517.1M in FY 2025, and operating income moved from a loss to $57.8M over the same span. Per the market data, the gross margin is 70.1%, operating margin 11.2%, and net margin 12.8%, with ROIC at 4.6%. Per the RQD rating, the Altman Z-Score is 26 and the Piotroski F-Score is 9/9; Debt/Equity is 0.03. Debt declined from $539.8M in FY 2023 to $43.4M in FY 2025, consistent with the forensic balance-sheet score.

Open Questions

  • What specific products and customer segments drive the $517.1M FY 2025 revenue, and how much is recurring?
  • What explains the swing from a $-74.4M net loss in FY 2023 to $66.4M net income in FY 2025, and how much is durable?
  • What do the 13F institutional filings and insider Form 4 transactions actually show, given the holders data is empty?
  • What is the basis for the "107% run" and "expected earnings beat" headlines, and what are the consensus estimates?
  • Why is EPS reported as N/A in the financials when the market data shows EPS (TTM) of 0.83?

VCYT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Veracyte Inc. (VCYT) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to VCYT Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

VCYT Bull vs. Bear Conversation Board β€” What's Your Call at $50.01?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON VCYT 🐻 33% BEARISH CONVICTION
1. Pick Your Side on VCYT:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk πŸ‚ BULLISH 🎯 Target: $61.56 (+18.0%)
πŸ“Œ Pinned Debate

πŸ”₯ Official Bull vs. Bear Debate: Is VCYT (B β€’ RQD 74/100) a Buy at $52.17?

Welcome to the VCYT (Veracyte Inc.) Roar Pit. Current RQD Composite is 74/100 (Roarable Buy β€” Good Risk/Reward) in Medical Specialities. Bulls point to operating leverage and sector positioning, while bears focus on valuation multiple compression (63.2x trailing P/E). Pick your side (πŸ‚ Bull or 🐻 Bear) and drop your price target below.

SK SkepticalCFA Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $40.69 (-22.0%)
Spot @ $52.17

Pump the brakes on VCYT β€” check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on VCYT, but look at what you are paying: 63.2x trailing P/E with 70.1% gross margins. Unless Veracyte Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

CA CashFlowKing Verified K Arena Trader πŸ‚ BULLISH 🎯 Target: $62.60 (+20.0%)
Spot @ $52.17

VCYT cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on VCYT, the market is fixating on short-term headline noise in Medical Specialities and ignoring the balance sheet and cash flow trajectory. At $52.17 (52-wk range $29.45 - $60.91), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%